Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment

Trial Profile

Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs Etirinotecan pegol (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2016 Status changed from completed to active, no longer recruiting.
    • 21 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 05 Aug 2015 Study details will be presented at the IASLC 16th World Congress on Lung Cancer, according to a Nektar Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top